A shadow economy for unapproved weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, based on recent findings.
Experimental Drug Acquiring Popularity Via Social Media
Retatrutide, which remains in clinical trials, is being promoted by online personalities for its alleged fat-burning properties. Viewers are urged to message these profiles privately for source information, while also obtaining discount codes.
Thriving Commerce on Messaging Platforms
Additionally, a robust market exists on messaging services, where groups with thousands of members share comparison photos, administration instructions and claims of rapid UK delivery. Vendors market the drug there before redirecting buyers to other platforms for purchases.
Understanding The Experimental Drug
This medication is an experimental injectable created by US drugmaker Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could help individuals reduce up to 25% of their total weight. Referred to as the “triple G”, the drug is being promoted online as the next Ozempic.
Healthcare Professionals Express Concerns
However, doctors and pharmacists have warned that the distribution of what is still an unapproved medication in the United Kingdom is worrisome and could lead to individuals injecting substances of unknown origin.
Several experts said the demand for retatrutide could be linked to the increasing cost of approved weight loss products such as Mounjaro.
Legal Position and Enforcement
Selling retatrutide on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed medication that must not be promoted or distributed for human use under the Human Medicines Regulations 2012.
Some influencers attempt to circumvent the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but promotion and distribution can still violate pharmaceutical, advertising, and customer regulations, risking penalties, prosecution or prison.
Service Response and Material Removal
Based on the social media company, the platform has taken down problematic content and prohibited associated keywords and search suggestions. The company said it was dedicated to maintaining the service secure and investing in strengthening enforcement strategies.
Digital Marketplace Activities
Investigations also found groups with up to 9,000 members marketing retatrutide using the platform's integrated discovery tool, which operates like a public directory. Entering “retatrutide” instantly brings up channels with thousands of users, populated with images of weight loss, glowing testimonials and step-by-step instructions for preparing or administering at residence.
After moments of entering one group, a seller shared WhatsApp details, where the majority of purchases take place. The seller provided an guidebook and guaranteed delivery within two days. When asked whether the substance was authentic, one seller said: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. None asked about weight, health issues or previous experience.
Item Information and Costs
Within these groups, posts display dark colored parcels with postal service stickers, claiming to contain new batches. One communication stated: “It took eight of us to load them this morning.”
Customers can choose between powder vials, prepared at home with purified liquid, or pre-filled pens usually priced at 160 pounds for 20 milligrams. When questioned how much time a injector should last, sellers give conflicting answers varying between a few weeks to “depends on your body”.
Platform Oversight and Safety Measures
A representative for Telegram stated it regularly monitored dangerous material on its service including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Medical Professional Cautions
“Individuals are administering substances they can’t verify. Even if the science behind retatrutide is sound, these online products may not contain what they claim,” stated a pharmacy expert, the head of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to current price rises for approved slimming drugs such as Mounjaro. “With prices increasing, individuals are turning to online platforms. But counterfeit treatments are highly risky. You can’t be certain what’s inside or whether the environment they were produced in was sterile,” she said.
Her team has previously seen individuals harmed by self-injection from unverified suppliers. “We recognize the disappointment, but buying from Telegram or communication platforms is taking chances with your health,” stated the doctor. “These substances could be contaminated or improperly measured.”
Manufacturer Position
A spokesperson from the pharmaceutical company said the substance was in third stage research studies and had not been evaluated or approved by any government authority anywhere in the world. “Consequently at this point no one can market [it] for human use,” they said, noting that any product “falsely representing itself as a Lilly experimental substance not yet authorized … may expose users to potentially significant health risks”.
